Protocol Ledger

NCT04593940 · Phase III · COMPLETED

Immune Modulators for Treating COVID-19

Interventional Phase III clinical trial protocol NCT04593940 sponsored by Daniel Benjamin in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-10-15 Enrollment: 1,971 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04593940
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,971 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04593940
Protocol FieldVerified Registry Value
NCT IdentifierNCT04593940
Consolidated Lead SponsorDaniel Benjamin
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,971 participants (ACTUAL)
Registered Start Date2020-10-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI